Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer A Chan

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNETMarc Garcia-Moure, Marisol Gonzalez-Huarriz, Sara Labiano, et al.
Nature Communications|November 15, 2024
VSV<sup>∆M51</sup> drives CD8<sup>+</sup> T cell-mediated tumour regression through infection of both cancer and non-cancer cellsJahanara Rajwani, Daniil Vishnevskiy, Madison Turk, et al.
The New England Journal of Medicine|September 16, 2024
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine TumorsJennifer A Chan, Susan Geyer, Tyler Zemla, et al.
Neuro-Oncology|April 1, 2015
Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtypeGuillaume Bergthold, Pratiti Bandopadhayay, Yujin Hoshida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Plos One|August 29, 2018
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsAlice L Yuan, Christian B Ricks, Alexandra K Bohm, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Journal of the National Cancer Institute|May 31, 2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meetingSimron Singh, Thomas A Hope, Emily B Bergsland, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNETMarc Garcia-Moure, Marisol Gonzalez-Huarriz, Sara Labiano, et al.
Nature Communications|November 15, 2024
VSV<sup>∆M51</sup> drives CD8<sup>+</sup> T cell-mediated tumour regression through infection of both cancer and non-cancer cellsJahanara Rajwani, Daniil Vishnevskiy, Madison Turk, et al.
The New England Journal of Medicine|September 16, 2024
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine TumorsJennifer A Chan, Susan Geyer, Tyler Zemla, et al.
Neuro-Oncology|April 1, 2015
Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtypeGuillaume Bergthold, Pratiti Bandopadhayay, Yujin Hoshida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type GliomaAnna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Plos One|August 29, 2018
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsAlice L Yuan, Christian B Ricks, Alexandra K Bohm, et al.
Cancer Research|June 25, 2009
Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz, Christine A Beckwith, Meredith M Regan, et al.
Journal of the National Cancer Institute|May 31, 2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meetingSimron Singh, Thomas A Hope, Emily B Bergsland, et al.
Pageof 19